A UK biopharma firm's lead drug candidate has now shown good
preclinical results for rheumatoid arthritis, adding to its
clinical efficacy in Alzheimer's.
Avidia has initiated a clinical trial for the novel inhibitor of a
protein for Crohn's disease as a potential treatment that belongs
to a new class of therapeutic proteins known as Avimer proteins.
Corgentech announced that its drug candidate was effective in
preclinical studies in reducing disease activity in models of
Crohn's disease and ulcerative colitis-both also referred to as
inflammatory bowel disease (IBD), which...